PCN126 A Cost IMPACT Analysis of Clonoseq® As a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic in Multiple Myeloma in Germany
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.263
https://www.valueinhealthjournal.com/article/S1098-3015(20)32519-5/fulltext
Section Title :
Section Order :
10209
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32519-5&doi=10.1016/j.jval.2020.08.263